Oncolytics Biotech Inc T.ONC

ONCY's GOBLET trial's pancreatic cohort exceeds expectations

[Noteable]

June 28, 202 - "With Stage 1's pre-specified efficacy threshold met after just the first three patients, the GOBLET trial's pancreatic cancer cohort is clearly exceeding expectations," said Dirk Arnold M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg, and primary investigator of the GOBLET trial.

The GOBLET study's pancreatic cancer cohort is evaluating the safety and efficacy of pelareorep in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab and the chemotherapeutic agents gemcitabine and nab-paclitaxel. Per the study's Simon two-stage design, any cohort meeting a pre-specified efficacy threshold in Stage 1 (defined as achieving a minimum number of objective radiologic responses by week 16) may be expanded to enroll additional patients in an optional Stage 2 study expansion.

In addition to evaluating the safety and efficacy of pelareorep-atezolizumab combinations, the study seeks to assess the potential of CEACAM6 and T cell clonality to serve as predictive biomarkers that may increase the probability of success in subsequent trials by informing patient selection. The study is being conducted at 14 clinical sites in Germany and is being managed by AIO, a leading academic cooperative medical oncology group.

[Noteable]

As background - Pandy et al (2019) found that high CEACAM6 expression is associated with low cytolytic T-cell activity in both basal and classical PDA subtypes and correlates with low levels of T-REG markers. The authors also found that CEACAM6, a key regulator affects several hallmarks of PDA including the fibrotic reaction, immune regulation, energy metabolism and is a novel

[Noteable]

Below is further background in a 2020 paper of CD47's fibrotic reaction in sclerodoma for example: "Scleroderma is a devastating fibrotic autoimmune disease. Current treatments are partly effective in preventing disease progression but do not remove fibrotic tissue. Here, we evaluated whether scleroderma fibroblasts take advantage of the “don’t-eat-me-signal” CD47 and whether blocking

[askretka]

I always thought the Keytruda Pelareorep last follow up data where several patients had stable disease was pretty significant considering that the patients are near dead after failing all other possible treatments. 5 year survival rates for Pancreatic cancer are something like 5-6% and 10 year 1% or less. With no real new treatments for Pancreatic cancer we could very well be in the running for a

[Noteable]

June 2022 - Preliminary results from ONCY's Goblet-1 pancreatic cancer cohort were presented at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022, showed that a strong efficacy signal was achieved by all patients receiving pelareorep + immunce checkpoint inhibitor (atezolizumab) which was manifested by all treated patients experiencing at least a

[Noteable]

In addition to evaluating the safety and efficacy of pelareorep-atezolizumab combinations, the study seeks to assess the potential of CEACAM6 and T cell clonality to serve as predictive biomarkers that may increase the probability of success in subsequent trials by informing patient selection.